Nirmal Bang

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

A Relationship Beyond Broking

External broker reports(aggregated public sources), Nirmal Bang

External broker reports(aggregated public sources)

Equity Bottom-Up

Sun Pharmaceutical Industries / Equity Bottom-Up

<div><div><div><div><ul><li>Sun Pharma reported revenue at Rs94,468mn, up 10.8% YoY but the same was down 4.2% QoQ.</li></ul><div><div><div><div><ul><li>India Branded Generics business reported sales at Rs30,956mn, up 15.9% YoY, but down 2.3% QoQ</li></ul><div><div><div><div><ul><li>US Formulations business reported sales at Rs29,246mn, up 8.5% YoY but down 1.6% QoQ.</li></ul></div></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Sun Pharma reported revenue at Rs94,468mn, up 10.8% YoY but the same was down 4.2% QoQ.India Branded Generics business reported sales at Rs30,956mn, up 15.9% YoY, but down 2.3% QoQUS Formulations business reported sales at Rs29,246mn, up 8.5% YoY but down 1.6% QoQ.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sun Pharma Industries - One-Time Costs Hit Earnings